Metastases To Central Nervous System
17 drugs6,567 FAERS reportsMedDRA PT
GET
/api/v1/reaction/metastases-to-central-nervous-systemReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
Drugs reporting Metastases To Central Nervous System (17)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Dextran 40811%
- 2Ceritinib1727.3%
- 3Zongertinib46.2%
- 4Tucatinib2954.4%
- 5Gefitinib3764.2%
- 6Afatinib2684.1%
- 7Margetuximab13.8%
- 8Lapatinib4783.1%
- 9Entrectinib462.8%
- 10Dabrafenib4902.4%
- 11Pertuzumab6622.2%
- 12Trastuzumab1,8332.1%
- 13Osimertinib6422.1%
- 14Trametinib4842.0%
- 15Vemurafenib2432.0%
- 16Durvalumab3251.7%
- 17Brigatinib240—
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Acquired Gene Mutation2 shared · 0.12
- Metastatic Malignant Melanoma2 shared · 0.12
- Palmar-plantar Erythrodysaesthesia Syndrome3 shared · 0.10
- Malignant Melanoma2 shared · 0.10
- Non-small Cell Lung Cancer2 shared · 0.10
- Pleural Effusion4 shared · 0.09
- Ejection Fraction Decreased2 shared · 0.09
- Hepatitis2 shared · 0.09
- Lung Neoplasm Malignant2 shared · 0.09
- Interstitial Lung Disease4 shared · 0.08
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.